Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 1
Submit an article Journal homepage
276
Views
15
CrossRef citations to date
0
Altmetric
Reviews

A review of economic impact of targeted oral anticancer medications

Chan ShenDepartments of Health Services Research and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Chun-Ru ChienDepartment of Radiation Oncology, China Medical University Hospital, 2b. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan
,
Daniel M GeynismanDepartment of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA
,
Fabrice SmieliauskasDepartment of Health Studies, The University of Chicago, Chicago, IL, USA
&
Ya-Chen T ShihDepartment of Medicine, Section of Hospital Medicine, Program in the Economics of Cancer, The University of Chicago, Chicago, IL, USACorrespondence[email protected]
Pages 45-69 | Published online: 30 Dec 2013

References

  • Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. Added value of molecular targeted agents in oncology. Ann. Oncol. 22(8), 1703–1716 (2011).
  • Jones S. Pharmacy practice issues with targeted therapy for lung cancer. Am. J. Health Sys. Pharm. 60(24 Suppl. 9), S11–S15 (2003).
  • Weingart SN, Brown E, Bach PB et al. NCCN task force report: oral chemotherapy. J. Natl Compr. Cancer Net. 6(Suppl. 3), S1–S14 (2008).
  • Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1), 110–115 (1997).
  • Benjamin L, Cotte FE, Philippe C, Mercier F, Bachelot T, Vidal-Trecan G. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment. Eur. J. Cancer 48(6), 912–920 (2012).
  • Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Dis. Med. 15(83), 231–241 (2013).
  • Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J. Natl Cancer Inst. 94(9), 652–661 (2002).
  • Mccowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br. J. Cancer 99(11), 1763–1768 (2008).
  • Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 126(2), 529–537 (2011).
  • Ganesan P, Sagar TG, Dubashi B et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am. J. Hematol. 86(6), 471–474 (2011).
  • Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J. Manag. Care Pharm. 12(7), 570–577 (2006).
  • Glanville J, Paisley S. Identifying economic evaluations for health technology assessment. Int. J. Technol. Assess. Health Care 26(4), 436–440 (2010).
  • Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Inter. Med. 151(4), 264–269, W264 (2009).
  • Timmers L, Beckeringh JJ, Van Herk-Sukel MP, Boven E, Hugtenburg JG. Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008. Pharmacoepidemiol. Drug Safety 21(10), 1036–1044 (2012).
  • Raborn ML, Pelletier EM, Smith DB, Reyes CM. Patient Out-of-Pocket Payments for Oral Oncolytics: Results From a 2009 US Claims Data Analysis. J. Oncol. Pract. 8(3 Suppl.), 9s–15s (2012).
  • Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J. Natl Compr. Cancer Netw. 6(9), 942–953 (2008).
  • Isla D, Gonzalez-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin. Transl. Oncol. 13(7), 460–471 (2011).
  • Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis. PharmacoEconomics 29(4), 331–341 (2011).
  • Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin. Ther. 30(4), 775–784 (2008).
  • Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. J. Med. Econom. 14(2), 159–166 (2011).
  • Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J. Manag. Care Pharm. 12(6), 472–478 (2006).
  • Doral Stefani S, Giorgio Saggia M, Vicino Dos Santos EA. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. J. Med. Econom. 11(3), 383–396 (2008).
  • Banz K, Bischoff H, Brunner M et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 74(3), 529–534 (2011).
  • Nuijten MJ, De Castro Carpeno J, Chouaid C et al. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer 76(3), 465–471 (2012).
  • Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S. Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clin. Econom. Outcomes Res. 4, 237–243 (2012).
  • Nadler E, Forsyth M, Satram-Hoang S, Reyes C. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. J. Thor. Oncol. 7(1), 212–218 (2012).
  • Purmonen T, Nuttunen P, Vuorinen R, Pyrhonen S, Kataja V, Kellokumpu-Lehtinen P. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncol. 49(6), 837–843 (2010).
  • Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br. J. Cancer 102(1), 80–86 (2010).
  • Ravasio R, Ortega C, Sabbatini R, Porta C. Bevacizumab plus interferon-alpha versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin. Drug Invest. 31(7), 507–517 (2011).
  • Choueiri TK, Mcdermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol. Oncol. 30(6), 848–855 (2012).
  • Duh MS, Dial E, Choueiri TK et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr. Med. Res. Opin. 25(8), 2081–2090 (2009).
  • Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors. J. Manag. Care Pharm. 16(7), 482–491 (2010).
  • Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transp. 42(1), 23–28 (2008).
  • Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharm. Econom. 25(6), 481–496 (2007).
  • Wu EQ, Johnson S, Beaulieu N et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr. Med. Res. Opin. 26(1), 61–69 (2010).
  • Armoiry X, Fagnani F, Benboubker L et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J. Clin. Pharm. Ther. 36(1), 19–26 (2011).
  • Durie B, Binder G, Pashos C, Khan Z, Hussein M, Borrello I. Total cost comparison in relapsed/refractory multiple myeloma. J. Med. Econom. 16(5), 614–622 (2013).
  • Chouaid C, Monnet I, Robinet G, Perol M, Fournel P, Vergnenegre A. Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr. Med. Res. Opin. 23(7), 1509–1515 (2007).
  • Horgan AM, Bradbury PA, Amir E et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann. Oncol. 22(8), 1805–1811 (2011).
  • Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J. Med. Econom. 16(2), 278–288 (2013).
  • Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network. Clin. Genitourin. Cancer 11(2), 115–120 (2013).
  • Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trecan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. J. Med. Econom. 16(1), 96–107 (2013).
  • Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr. Med. Res. Opin. 26(12), 2861–2869 (2010).
  • Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27(2), 80–81, 149 (2013).
  • Zafar SY, Abernethy AP. Financial toxicity, Part II: how can we help with the burden of treatment-related costs? Oncology (Williston Park) 27(4), 253–254, 256 (2013).
  • Zafar SY, Peppercorn JM, Schrag D et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18(4), 381–390 (2013).
  • Pfister DG. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J. Clin. Oncol. 31(28), 3487–3489 (2013).
  • Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretium--the just price. J. Clin. Oncol. 31(28), 3600–3604 (2013).
  • Carroll J. Oral/infusion cancer drug parity begins to raise health plan costs. Manag. Care 21(1), 7–8 (2012).
  • Dunn R, Gochenauer G. The promise of oral anticancer agents: addressing compliance and affordability. 6(5) (2012).
  • Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
  • Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786–792 (2005).
  • Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
  • Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in kras are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900–5909 (2005).
  • Jang S, Atkins MB. Treatment of BRAF mutant melanoma: the role of vemurafenib and other therapies. Clin. Pharmacol. Ther. (2013) (Epub ahead of print).
  • Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. Clin. Pharmacol. Ther. (2013) (Epub ahead of print).
  • Conti RM, Rosenthal MB, Polite BN, Bach PB, Shih YC. Infused chemotherapy use in the elderly after patent expiration. Am. J. Manag. Care 18(5), e173–178 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.